Milestone Pharmaceuticals Inc.

NasdaqGS:MIST 株式レポート

時価総額:US$93.3m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Milestone Pharmaceuticals 将来の成長

Future 基準チェック /26

Milestone Pharmaceuticalsは、50.8%と66.4%でそれぞれ年率50.8%で利益と収益が成長すると予測される一方、EPSはgrowで52.6%年率。

主要情報

50.8%

収益成長率

52.6%

EPS成長率

Pharmaceuticals 収益成長27.6%
収益成長率66.4%
将来の株主資本利益率n/a
アナリストカバレッジ

Low

最終更新日30 May 2024

今後の成長に関する最新情報

Recent updates

Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely

Jun 07
Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely

Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?

Sep 13
Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?

We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

Mar 07
We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

Oct 15
We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth

Jun 24
We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth

We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely

Feb 25
We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely

We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow

Aug 25
We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow

Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth

Apr 02
Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth

What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition

Jan 15
What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition

First patient enrolled in Milestone Pharmaceuticals' late-stage study of etripamil in PSVT

Nov 18

Milestone Pharmaceuticals EPS beats by $0.09

Nov 13

業績と収益の成長予測

NasdaqGS:MIST - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/202630-35-30-142
12/31/20254-72-49-384
12/31/2024N/A-43-30-264
3/31/2024N/A-55-42-41N/A
12/31/20231-60-47-46N/A
9/30/20235-59-50-49N/A
6/30/20236-59-49-49N/A
3/31/20236-59-53-52N/A
12/31/20225-58-53-52N/A
9/30/20222-62-52-52N/A
6/30/2022N/A-62-50-50N/A
3/31/202215-44-35-35N/A
12/31/202115-43-33-33N/A
9/30/202115-35-30-30N/A
6/30/202115-32-28-28N/A
3/31/2021N/A-46-45-45N/A
12/31/2020N/A-50-51-51N/A
9/30/2020N/A-60-59-59N/A
6/30/2020N/A-60-60-60N/A
3/31/2020N/A-61-55-54N/A
12/31/2019N/A-55-52-51N/A
9/30/2019N/A-47-42-42N/A
6/30/2019N/A-40-39-39N/A
3/31/2019N/A-29-31-31N/A
12/31/2018N/A-23-21-21N/A

アナリストによる今後の成長予測

収入対貯蓄率: MIST今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: MIST今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: MIST今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: MISTの収益 ( 66.4% ) US市場 ( 8.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: MISTの収益 ( 66.4% ) 20%よりも速いペースで成長すると予測されています。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: MISTの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です


成長企業の発掘